Would the utilization of sFlt-1/PlGF ratio in clinical practice prevent unnecessary hospital admissions of cases with preeclampsia? DOI Creative Commons
Majed Alhudhud,

Hina Yousuf,

Hanan Aljohani

и другие.

Hypertension in Pregnancy, Год журнала: 2024, Номер 43(1)

Опубликована: Дек. 2, 2024

Objectives Preeclampsia (PET) is a serious pregnancy complication with potential adverse maternal and fetal outcomes. Recent research has examined the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio for predicting PET. The study aimed to assess efficacy of sFlt-1/PlGF in ruling out unnecessary hospital admission

Язык: Английский

Would the utilization of sFlt-1/PlGF ratio in clinical practice prevent unnecessary hospital admissions of cases with preeclampsia? DOI Creative Commons
Majed Alhudhud,

Hina Yousuf,

Hanan Aljohani

и другие.

Hypertension in Pregnancy, Год журнала: 2024, Номер 43(1)

Опубликована: Дек. 2, 2024

Objectives Preeclampsia (PET) is a serious pregnancy complication with potential adverse maternal and fetal outcomes. Recent research has examined the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio for predicting PET. The study aimed to assess efficacy of sFlt-1/PlGF in ruling out unnecessary hospital admission

Язык: Английский

Процитировано

0